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Abstract: Collagen prolyl 4-hydroxylase 1 (C-P4H1) is an α-ketoglutarate (α-KG)-dependent dioxygenase
that catalyzes 4-hydroxylation of proline on collagen. C-P4H1-induced prolyl hydroxylation is required
for proper collagen deposition and cancer metastasis. Therefore, targeting C-P4H1 is considered
a potential therapeutic strategy for collagen-related cancer progression and metastasis. However,
no C-P4H1 inhibitors are available for clinical testing, and the high content assay is currently not
available for C-P4H1 inhibitor screening. In the present study, we developed a high-throughput
screening assay by quantifying succinate, a byproduct of C-P4H-catalyzed hydroxylation. C-P4H1 is
the major isoform of collagen prolyl 4-hydroxylases (CP4Hs) that contributes the majority prolyl
4-hydroxylase activity. Using C-P4H1 tetramer purified from the eukaryotic expression system,
we showed that the Succinate-GloTM Hydroxylase assay was more sensitive for measuring C-P4H1
activity compared with the hydroxyproline colorimetric assay. Next, we performed high-throughput
screening with the FDA-approved drug library and identified several new C-P4H1 inhibitors, including
Silodosin and Ticlopidine. Silodosin and Ticlopidine inhibited C-P4H1 activity in a dose-dependent
manner and suppressed collagen secretion and tumor invasion in 3D tissue culture. These C-P4H1
inhibitors provide new agents to test clinical potential of targeting C-P4H1 in suppressing cancer
progression and metastasis.
Keywords: prolyl hydroxylation; collagen; high-throughput screening; extracellular matrix; cancer invasion

1. Introduction
Collagen is the most abundant extracellular matrix (ECM) protein in the human body [1]. Increased
collagen expression and deposition is associated with fibrosis and tumor progression, and reducing
collagen production is sufficient to inhibit the progression of these diseases [2–4]. Collagen is
synthesized and forms the triple helix structure in the ER [5]. The basic unit of the triple-helical
structure is Gly-pro-X, and the proline is often hydroxylated. Prolyl hydroxylation is required for
the sharp twisting of collagen helix and secretion of collagen protein [6]. Therefore, the proline
hydroxylation pathway is considered a promising target to halt collagen expression and deposition.
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Collagen hydroxylation is catalyzed by collagen prolyl 4-hydroxylase (C-P4H) [7], a Fe2+ and
2-oxoglutarate-dependent enzyme [7]. C-P4H contains two α subunits (P4HA) and two β subunits
(P4HB), and each α subunit contains the peptide substrate binding domain and the catalytic domain [8].
Three P4HA isoforms have been characterized in mammalian cells with different tissue distribution.
It has been shown that P4HA1 contributes more than 50% of prolyl 4-hydroxylase activity in most cell
types and considered the major isoform [9].
Increased collagen expression or deposition is associated with cancer development, such as
gastric cancer [10], breast cancer [11], bladder cancer [12], and colorectal cancer [13]. Binding of
collagen to its receptors such as discoidin domain receptors (DDRs) [14] and integrin [15,16] activates
downstream signal pathways, and subsequently enhances cancer cell migration and invasion [17,18].
It has been shown that P4HA1 expression is induced during cancer development and progression.
Silence of P4HA1 is sufficient to inhibit cancer metastasis and sensitize cancer cells to chemotherapeutic
agents [19]. Increased P4HA1 expression has also been detected in fibrosis, and inhibition of P4HA1
reduces hepatic collagen accumulation and suppresses the fibrosis progression [20]. Overexpression of
P4HA1 increases atherosclerotic plaque in apolipoprotein E-deficient mice, suggesting a potential role
of P4HA1 in coronary thrombosis [21]. These results suggest that P4HA1 is a potential therapeutic
target for cancer and fibrosis.
A HPLC-based assay has been developed to measure C-P4H1 activity based on P4H-catalyzed
turnover of a flp-containing peptide [22]. This assay has been used to examine small molecule activities
in the small scale, resulting in the identification of several chemicals as C-P4H1 inhibitor, including
ethyl-3,4-dihydroxybenzoic acid (DHB) and 2,20 -bipyridine (bipy) [23,24]. Although their inhibitory
activities on collagen secretion has been confirmed in tissue culture, none of them has been approved
for clinical use. There is an urgent need to identify potent C-P4H1 inhibitors that can be used in clinic
for the treatment of collagen-dependent diseases.
Here, we described a novel method to measure C-P4H1 activity by quantifying the product
of prolyl hydroxylation, succinate. We developed a high-throughput screening assay based on this
method and identified Silodosin and Ticlopidine as novel C-P4H1 inhibitors from the FDA-approved
drug library. Further examining their biological activity in vivo may identify Silodosin and Ticlopidine
as potential drugs targeting C-P4H1-dependent cancer progression.
2. Results
2.1. Protein Expression and Purification
C-P4H1 contains two α1 subunits and two β subunits. The β subunit is the protein disulfide
isomerase (PDI) [25], which is required for catalytic activity of the α subunit [26]. Therefore, it is
necessary to purify the C-P4H1 tetramer for measuring its activity. In previous studies, C-P4Hs were
often expressed and purified from E. coli [27]. Given the important function of post modification for
protein activity, we decided to use mammalian cell lines for C-P4H1 expression. HEK-293 FT and
CHO have been widely used to expression exogenous proteins with high transfection efficiency [28].
P4HA1 and P4HB expression constructs with flag tag were transfected into HEK-293FT cells. The cells
were harvested 48 h after transfection, and P4HA1 expression was examined by western blotting with
antibodies against P4HA1 and Flag (Figure 1A).
Next, we compared C-P4H1 expression in HEK-293FT cells and CHO cells. P4HA1 and P4HB
expression constructs were transfected into these two cell lines, and the recombinant C-P4H1 was
purified with anti-Flag M2 beads. We found that the P4H α1 was expressed and purified at much
higher levels in HEK-293FT cells than in CHO cells (Figure 1B,C). Therefore, HEK-293FT cells were
used to generate C-P4H1 for the following experiments.
To determine whether the C-P4H1 tetramer was purified with anti-Flag M2 beads, we performed
native gel electrophoresis to analyze the purified protein. Coomassie blue staining results showed that
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the purified protein presented at three major bands, and tetramer, dimer and single subunit were all
detected (Figure 1D).
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Figure 1. C-P4H1 is expressed and purified from HEK-293FT cells. (A) Expression of C-P4H1 was
Figure 1. C-P4H1 is expressed and purified from HEK-293FT cells. (A) Expression of C-P4H1 was
analyzed by western blot with anti-P4H1α and anti-flag antibody. Cell lysates were collected from
analyzed by western blot with anti-P4H1α and anti-flag antibody. Cell lysates were collected from
control and 293 FT cells transfected with P4HA1 and P4HB constructs. (B) Ponceau staining showed
control and 293 FT cells transfected with P4HA1 and P4HB constructs. (B) Ponceau staining showed the
the expression and purification of C-P4H1 from 293 FT cells and CHO cells. The letters indicate: L
expression
and purification of C-P4H1 from 293 FT cells and CHO cells. The letters indicate: L (Total cell
(Total cell lysates with HGLB), Un (unbinding samples after cell lysates incubated with M2 gel), W
lysates
with
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Unsample
(unbinding
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afterfirst
celltime
lysates
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(The remaining
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(C) Western
elution).
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blot analysis
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withgel
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(D) Purified
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Native PAGE
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Native PAGE gel with Coomassie Blue staining; BSA was included as a control.
included by
as a8%
control.

2.2. Screening Method Confirmation
2.2. Screening Method Confirmation
The colorimetric assay has been used to evaluate hydroxyproline and quantified collagen levels in
The colorimetric assay has been used to evaluate hydroxyproline and quantified collagen levels
ECM
[29–31], in which hydroxyproline reacts with p-dimethylaminobenzaldehyde (DMAB, Ehrlich’s
in ECM [29–31], in which hydroxyproline reacts with p-dimethylaminobenzaldehyde (DMAB,
reagent)
producetothe
chromophore
(Figure 2B).
However,
this assaythis
hasassay
not been
used
to characterize
Ehrlich’storeagent)
produce
the chromophore
(Figure
2B). However,
has not
been
used to
C-P4Hs
inhibitors.
Bioluminescence-based
Succinate-GloTM
Hydroxylase
assay
(Figure
2B)
has been
characterize C-P4Hs inhibitors. Bioluminescence-based Succinate-GloTM Hydroxylase assay (Figure
used
to
measure
protein
hydroxylase
activity
with
the
high
content
potential
[32].
We
compared
2B) has been used to measure protein hydroxylase activity with the high content potential [32]. Wethese
two
assays with
concentration
of C-P4H1.
The ODof
value in the
560 C-P4H1.
compared
thesedifferent
two assays
with different
concentration
The hydroxyproline
OD560 value in reaction
the
was
moderately increased
at 0.25
µM C-P4H1
compared
negative
andtofurther
increasing
hydroxyproline
reaction was
moderately
increased
at 0.25to
µM
C-P4H1control,
compared
negative
control, the
and further increasing the concentration of C-P4H1 had little effect on the OD value (Figure 2C).
Luminescence values in the Succinate-Glo™ assay were induced by C-P4H1 in a dose-dependent
manner, and two-fold induction was detected at 0.25 µM of C-P4H1(Figure 2D). These results
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One-way ANOVA analysis. (E) MT-P4HA1 activity was evaluated with the Succinate-GloTM
Hydroxylaseassay
assayat
at different
n = 3.
no statistical
significance.
The data displayed
Hydroxylase
differentconcentrations.
concentrations.
n ns,
= 3.
ns, no statistical
significance.
The data
as
means
±
standard
deviation
(SD).
displayed as means ± standard deviation (SD).

To further
evaluate
the Succinate-Glo™
assay,
tested
varied concentration
of
It has
been shown
thatreliability
mutation of
of P4HA1
H483 abolished
thewe
prolyl
hydroxylase
activity without
peptide
GPPG
(Figure 3A)
α-KG
(Figure
3B) into
in the
hydroxylation
any
impactsubstrate
on tetramer
formation
[33].and
We hydroxyl
cloned thedonor
mutant
P4HA1
H483S
pcDNA
3.1 vector.
The mutant protein (MT-C-P4H1) was expressed in HEK-293FT cells and purified using the same
protocol with the wild type C-P4H1 (WT-C-P4H1). We found that the mutant C-P4H1 failed to
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increase the luminescence values in the Succinate-Glo™ assay (Figure 2E). These results indicate that
Succinate-Glo™ assay specifically detects prolyl hydroxylase activity of C-P4H1.
To further evaluate reliability of the Succinate-Glo™ assay, we tested varied concentration of
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW
5 of 13
peptide substrate GPPG (Figure 3A) and hydroxyl donor α-KG (Figure 3B) in the hydroxylation reaction,
respectively.
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Figure 3. Evaluation of the Succinate-GloTM Hydroxylase assay for analyzing C-P4H1 activity. (A)
Figure 3. Evaluation of the Succinate-GloTM Hydroxylase assay for analyzing C-P4H1 activity. (A) Bar
Bar graph showing the C-P4H1 (200 nM) activity at different concentrations of 2-KG. n = 3. (B) Bar
graph showing the C-P4H1 (200 nM) activity at different concentrations of 2-KG. n = 3. (B) Bar graph
graph showing the C-P4H1 (200 nM) activity at different concentrations of substrate peptide
showing the C-P4H1 (200 nM) activity at different concentrations of substrate peptide GPPGOET. n = 3.
GPPGOET. n = 3. (C) Curve measurement of the inhibitory activity of DHB in C-P4H1 (200 nM)
(C) Curve measurement of the inhibitory activity of DHB in C-P4H1 (200 nM) reaction. All the ATP
reaction. All the ATP signals produced by the plate reader were normalized with control. n = 3. (D)
signals
produced
by the
reader were normalized
withassay
control.
n =absence
3. (D) of
DHB
had little
effect
DHB had
little effect
onplate
the Succinate-GloTM
Hydroxylase
in the
C-P4H1.
All the
onATP
the Succinate-GloTM
Hydroxylase
assay
in
the
absence
of
C-P4H1.
All
the
ATP
signals
produced
signals produced by the plate reader were normalized with control, control value is 1. n = 3. ns
bymeans
the plate
reader were
normalized
with
control,
is 1. deviation
n = 3. ns(SD).
means no significant
no significant
statistic.
The data
displayed
ascontrol
means ±value
standard
statistic. The data displayed as means ± standard deviation (SD).

2.3. Inhibitory Screening and Verification
Repurposing FDA-approved drugs is a popular strategy to facilitate clinical studies of new
therapeutic targets [36]. To identify new C-P4H1 inhibitors that can be tested in clinic, we performed
a moderate scale screening with the bioluminescence-based assay using more than 1400 FDAapproved chemicals. We identified over 40 chemicals (Figure 4A) with greater or similar inhibitory
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Repurposing FDA-approved drugs is a popular strategy to facilitate clinical studies of new
therapeutic targets [36]. To identify new C-P4H1 inhibitors that can be tested in clinic, we performed a
moderate scale screening with the bioluminescence-based assay using more than 1400 FDA-approved
chemicals.
identified
over
40 chemicals (Figure 4A) with greater or similar inhibitory6 of
ability
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2020,
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compared to DHB. We further tested the inhibitory activities of two drugs, Silodosin and Ticlopidine,
compared
to DHB. We
further
the inhibitory
of two
drugs, Silodosinmanner
and
at ability
different
concentration.
Both
drugstested
inhibited
C-P4H1 activities
activity in
a dose-dependent
Ticlopidine,
at
different
concentration.
Both
drugs
inhibited
C-P4H1
activity
in
a
dose-dependent
(Figure 4B,D). Interestingly, Silodosin showed a faster kinetic property compared to ticlopidine,
manner (Figure
4B,D). chemical-protein
Interestingly, Silodosin
showed
a faster kinetic
property
compared
suggesting
the different
interaction
mechanism
between
two drugs.
The totwo
ticlopidine,
suggesting
the
different
chemical-protein
interaction
mechanism
between
two
drugs.
The
chemicals had little effect on the luminescence assay in the absence of C-P4H1 (Figure 4C,E), indicating
two chemicals had little effect on the luminescence assay in the absence of C-P4H1 (Figure 4C,E),
that Silodosin and Ticlopidine specifically inhibited the C-P4H1 activity in vitro.
indicating that Silodosin and Ticlopidine specifically inhibited the C-P4H1 activity in vitro.

Figure4.4. C-P4H1
identified
withwith
the high-throughput
screening
assay from
thefrom
FDA-the
Figure
C-P4H1inhibitors
inhibitorsareare
identified
the high-throughput
screening
assay
approved drug library. (A) The frequency for relative activity of P4H1 at the presence of each
FDA-approved drug library. (A) The frequency for relative activity of P4H1 at the presence of each
chemical. Over 1400 FDA-approved drugs were screening in the 384 well plate or 96-well plate at 50
chemical. Over 1400 FDA-approved drugs were screening in the 384 well plate or 96-well plate at 50
µM. 50 µM DHB was used as a positive control in each plate. All the ATP signals produced by the
µM. 50 µM DHB was used as a positive control in each plate. All the ATP signals produced by the
plate
reader
were
normalized
with
the
equation:
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒
𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
value o f samples
with chemicals
plate reader were normalized with the equation: relative activity = value o f control sample without chemicals . *,
. *, the relative activity of C-P4H1 in the presence of DHB. (B)
the relative activity of C-P4H1 in the presence of DHB. (B) Silodocin inhibitory activity was analyzed
activityAll
wasthe
analyzed
at different
concentrations.
All the
ATPwere
signals
produced to
at Silodocin
different inhibitory
concentrations.
ATP signals
produced
by the plate
reader
normalized
by
the
plate
reader
were
normalized
to
vehicle
control,
control
value
is
1;
n
=
3.
(C)
Silodocin
did not
vehicle control, control value is 1; n = 3. (C) Silodocin did not inhibit the Succinate-GloTM Hydroxylase
inhibit
the
Succinate-GloTM
Hydroxylase
assay
in
the
absence
of
WT-P4H1;
n
=
3.
(D)
Ticlopidine
assay in the absence of WT-P4H1; n = 3. (D) Ticlopidine inhibitory activity was analyzed at different
inhibitory activity was analyzed at different concentrations; 200 nM C-P4H1 in the reaction. The Cconcentrations; 200 nM C-P4H1 in the reaction. The C-P4H1 activities in ticlopidine-treated samples
P4H1 activities in ticlopidine-treated samples were normalized with vehicle control, control value is
were normalized with vehicle control, control value is 1; n = 3. (E) Ticlopidine did not inhibit the
1; n = 3. (E) Ticlopidine did not inhibit the Succinate-GloTM Hydroxylase assay in the absence of WTSuccinate-GloTM Hydroxylase assay in the absence of WT-P4H1; n = 3. The data displayed as means ±
P4H1; n = 3. The data displayed as means ± standard deviation (SD).
standard deviation (SD).

To determine whether the identified potential inhibitors suppress the C-P4H1 activity in tissue
To determine whether the identified potential inhibitors suppress the C-P4H1 activity in tissue
culture, we treated HS-578T cells with Silodosin or Ticlopidine for 48 h. Since collagen maturation
culture, we treated HS-578T cells with Silodosin or Ticlopidine for 48 h. Since collagen maturation
and secretion was regulated by the C-P4H1, conditioned media were collected from control and
and secretion was regulated by the C-P4H1, conditioned media were collected from control and
Silodosin- or Ticlopidine-treated cells for western blot analysis. We found that treatment with
Silodosin- or Ticlopidine-treated cells for western blot analysis. We found that treatment with Silodosin
Silodosin or Ticlopidine reduced protein levels of type I collagen in the conditioned media (Figure
or5A,B).
Ticlopidine
reduced
protein
of type
I collagen can
in the
conditioned
mediain(Figure
These results
suggest
thatlevels
Silodosin
and Ticlopidine
inhibit
C-P4H1 activity
vivo. 5A,B).
These results suggest that Silodosin and Ticlopidine can inhibit C-P4H1 activity in vivo.
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Figure 5. Silodocin and ticlopidine inhibit collagen deposition and cancer cell invasion. (A) Western
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(A) Western
blot analyzed
levels
of type I collagen
conditionaldeposition
medium of HS578
cells, The
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were treated
with Silodosin
10 µMI and
20 µM. in
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Western blot analyzed
levels
type I collagen
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medium
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medium
cells,20
TheµM.
cells (B)
wereWestern
treated with
Ticlopidine
at 10
µM and
µM.I (C)
Invasiveness
with Silodosin
at of
10HS578
µM and
blot
analyzed
levels
of 20
type
collagen
in conditional
medium of HS578 cells, The cells were treated with Ticlopidine at 10 µM and 20 µM. (C) Invasiveness
of MDA-MB-231 cells was examined in 3D culture assay in the presence or absence of Silodosin and
Ticlopidine. The cells were with Silodosin or Ticlopidine at 10 µM and 20 µM, and images were taken
after 48 h. Scale bar, 100 µm. (D) Dot blot graph quantified invasive branching structures in panel C.
One-way ANOVA analysis; n ≥ 20. *** p ≤ 0.001. (E) Phase images of control and Hs-578 cells treated
with Silodosin and Ticlopidine at 10 µM and 20 µM in 3D culture assay. Images were taken at 24 h after
treatment. Scale bar, 100 µm. (F) Dot blot graph quantified invasive branching structures in panel E.
One-way ANOVA analysis; n ≥ 20. *** p ≤ 0.001.
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It has been shown that silence of P4HAs suppress invasive tumor growth in three-dimensional
(3D) tissue culture model [19,37]. 3D culture model has been widely used to evaluate drug effect [38].
MDA-MB-231 cells and HS-578T cells are triple-negative breast cancer cell lines with invasive
phenotypes in 3D culture model [39]. To further evaluate the inhibitory ability of these chemicals
in tumor progression, we treated these two cell lines with Silodosin and Ticlopidine in 3D culture.
Both chemicals significantly reduced invasive branching structures of MDA-MB-231 cells (Figure 5C,D)
and HS-578T cells (Figure 5E,F). Invasive branching structure of cancer cells in 3D culture is associated
with tumor invasion and aggressive phenotypes [15,19,37]. We and others showed previously that
knocking down P4HA1 inhibited invasive branching in triple-negative breast cancer cells but had very
little effect on cell proliferation [19,37]. To test whether Silodosin or Ticlopidine treatment inhibits
tumor cell proliferation, we incubated the MDA-MB-231 and HS-578T cells with these two drugs
and analyzed cell number and viability with CCK-8 kit. We found that treatment with Silodosin or
Ticlopidine had little effect on cell proliferation in 2D culture (Data are not shown). These results
demonstrate that the C-P4H1 inhibitors identified from the Succinate-Glo™ assay suppressed invasive
phenotypes of triple-negative breast cancer cells.
3. Discussion
In the present study, we developed a new method to quantify the C-P4H1 activity by measuring
succinate levels. Using the high-throughput screening assay based on this method, we identified
several new C-P4H1 inhibitors, including Silodosin and Ticlopidine, from the FDA-approved drug
library. We further confirmed that treatment with Silodosin and Ticlopidine reduced collagen secretion
and suppressed invasive phenotypes of breast cancer cells in 3D culture.
To develop a better method to quantify the C-P4H1 activity, we compared the hydroxyproline
colorimetric assay to measure hydroxyproline and Succinate-GloTM Hydroxylase assay to measure
succinate levels. We found that the latter is more sensitive for measuring the C-P4H1 activity.
One potential reason for the reduced sensitivity in the hydroxylation colorimetric assay is the short
peptide length and Pro position of the substrate compared to collagen protein [40]. Thus, using longer
peptide as a substrate may increase the hydroxylation reaction rate and improve the colorimetric
assay sensitivity. As mentioned above, HPLC has been used to identify small molecules that inhibit
the C-P4H1 activity. Compared with the HPLC-based assay, the method that we developed with
Succinate-GloTM Hydroxylase assay has the potential for large scale screening.
Using the Succinate-GloTM Hydroxylase assay, we identified more than 40 potential C-P4H1
inhibitors from the FDA-approved drug library. These inhibitors have been used for the treatment of
various diseases, but most of them have not been tested in collagen-related diseases. Interestingly,
we also found that several chemicals enhanced the enzyme activity, indicating that this method can be
used to identify potential C-P4H1 activators. Collagen deficiency is associated with tissue adhesion
diseases, including Ehlers–Danlos Syndrome and Osteoporosis [41]. Enhancing collagen producing by
inducing C-P4H1 activity is a potential strategy for the treatment of these diseases.
One limitation for the method that we developed is that the Succinate-GloTM Hydroxylase assay
does not directly measure C-P4H1 activity. Chemicals that affect the conversion of succinate to ATP
and luciferase reaction may be falsely identified from screening; therefore, the potential inhibitors
and activators identified from the screening needs to be further verified with the Succinate-GloTM
Hydroxylase assay in the absence of C-P4H1.
Most of the identified C-P4H1 inhibitors works as α-KG mimics or Fe2+ chelating agents [23]. It is
not clear whether the inhibitors that we identified function through the same mechanism; therefore, it is
important to compare the molecular structure of these inhibitors with those previously identified and
determine how these inhibitors interacted with C-P4H1 in the future. The Quantitative structure-activity
relationships (QSAR) play important role in drug design and structure optimization [42,43]. We also
plan to perform the QSAR analysis to identify more potent C-P4H1 inhibitors.
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In summary, we identified several C-P4H1 inhibitors from the FDA-approved drug library using
the Succinate-GloTM Hydroxylase assay. We showed that two of them, Silodosin and Ticlopidine,
inhibited collagen secretion and invasive tumor growth in tissue culture model. Further evaluating
their activity in vivo may identify new drugs to target C-P4H1 induced cancer progression.
4. Martials and Methods
4.1. Cell Culture and 3D Culture Assay
MDA-MB-231 cells (ATCC) were cultured in DMEM/F12 (Sigma, St. Louis, MO, USA) with 10%
fetal bovine serum (Invitrogen, Carlsbad, CA, USA). HS-578 (ATCC) cells were cultured in DMEM
(Sigma) with 10% fetal bovine serum. 3D laminin-rich extracellular matrix (3D lrECM) on-top cultures
were prepared by trypsinization of cells from tissue culture plastic [37]. Growth Factor Reduced BD
Matrigel™ was plated on the bottom of the cell culture dish. MDA-MB-231 and HS-578 cells were
seeded on the top of the Matrigel layer, and additional medium containing 10% Matrigel was added
on the top. The cells lines were maintained below 10 passages.
4.2. Cell Viability Assay
To analyze cell viability in response to drug treatment, MDA-MB-231 and HS-578 cells were
seeded into 96-well plate with the density of 3000 cells per well. Following the cell adhesion, chemicals
were added and treated for 48 h. The cell viability was measured by the cell counting kit-8 (Sigma).
4.3. CP4H1 Expression and Purification
The CP4Hα and CP4Hβ gene were amplified with flag sequence then cloned into pcDNA 3.1
vector, respectively. Following primers were used for cloning; CP4Hα-N: AACGCTAGCGCCACCAT
GATCTGGTATATATTAAT; CP4Hα-C: ACTGGGATCCTCACTTATCGTC GTCATCCTTGTAATCTTCC
AATTCTGACAACGTAC; CP4Hβ-N: AACGCTAGCGCCACCATGCTGCGCCGCGCTCTGCT;
CP4Hβ-C: ACTGGGATCCTTACTTATCGTCGTCATCCTTGTAATCCAGTTCATCTTTCACAGCTT.
pcDNA 3.1-CP4Hα-flag and pcDNA 3.1-CP4Hβ-flag plasmids were transfected into 293 FT cells with
the Fugene reagent (Promega, Madison, WI, USA). Following 48 h’ transfection, cells were washed
by phosphate-buffered saline (PBS) and lysed with HGLB (10 mM Tris-HCl pH 7.5, 10 mM NaCl,
2 mM EDTA, 0.5% Triton X-100) containing cocktail proteinase inhibitors (Sigma). Lysates were
incubated with M2 gel (Sigma) at cold room for at least4 h, washed with NET2 buffer, and then eluted
with 250 µg/mL 3× flag peptide (GP10149). The solution containing CP4H1 was concentrated with
centrifugal filters (Sigma) and replaced with protein storing buffer (150 mM NaCl, 50 mM HEPES pH
7.4). The purified CP4H1 was subjected to native gel or SDS-PAGE gel.
4.4. Western Blot
Chemical treated Hs578 cells were lysed in 2% sodium dodecyl sulfate (SDS) in PBS buffer
containing phosphatase and protease inhibitor cocktails (Sigma). Protein concentration was measured
using Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Equal amounts
of protein lysates or cell conditional medium (normalized to cell numbers) were subjected to SDS
gel electrophoresis, immunoblotted with primary antibodies (Anti-Collagen I antibody, ab34710;
Anti-tubulin, Cell Signaling 2148)) and DyLight 680/800-conjugated secondary antibodies (DyLight
680-conjugated goat anti-rabbit IgG secondary antibody Thermo Fisher Scientific, 35569; DyLight
800-conjugated goat anti-mouse IgG secondary antibody Thermo Fisher Scientific, SA5-35521).
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4.5. Measuring Human CP4H1 Activity with Hydroxyproline Colorimetric Assay and Succinate-GloTM
Hydroxylase Assay
4.5.1. Human CP4H1 Activity Assay
Human CP4H1 activity assays were carried out at room temperature in 10 mM HEPES buffer
containing 10 mM NaCl, pH 7.4. Mix with human CP4H1 (200 nM), peptide substrate (GlyProProGlyOEt,
500 µM), FeSO4 (50 µM), catalase (0.1 mg/mL), ascorbate (2 mM), and α-ketoglutarate (100 µM).
FeSO4 was prepared freshly in 10 mM HCl prior to each time use. Following one-hour reaction,
the reaction solution was subjected to Hydroxyproline Colorimetric Assay and Succinate-GloTM
Hydroxylase assay, respectively.
4.5.2. Hydroxyproline Colorimetric Assay
100 µL of the Chloramine-T reagent (0.282 g chloramine-T, 1 mL n-propanol, 1 mL demineralized
water, and 8 mL stock buffer, stock buffer consisting of 0.24 M citric acid, 0.88 M sodium acetate
trihydrate, 0.88 M anhydrous sodium acetate, 0.21 M acetic acid and 0.85 M sodium hydroxide, pH 6.1)
was added to each hydroxyproline sample and incubate at room temperature for 5 min. 100 µL of
the DMAB reagent (2 g dimethylaminobenzaldehyde dissolved in 1.25 mL n-propanol and 2.75 mL
perchloric acid) was added to each well and incubate for 90 min at 60 ◦ C. The reaction was measure
with a microplate reader (BioTek, Winooski, VT, USA) at 560 nm.
4.5.3. Succinate-GloTM Hydroxylase Assay
Succinate-GloTM Hydroxylase assay was performed as the protocol described (Promega, V7991).
Briefly, after the hCP4H1 enzyme reaction, 10 µL Succinate Detection Reagent I was added. The mixture
was shanked for 30 s and incubated at room temperature for 60 min. 20 µL of Succinate Detection
Reagent II was added to each well and incubated at room temperature for 10 min. The luminescence
was measured with a plate-reading luminometer (BioTek).
4.6. High-Throughput Screening
All the chemicals (50 µM) were incubated with human C-P4H1 (200 nM) at least 30 min on ice.
Then mix with peptide substrate (GlyProProGlyOEt, 500 µM), FeSO4 (50 µM), catalase (0.1 mg/mL),
ascorbate (2 mM), and α-ketoglutarate (100 µM) to react 1 h at room temperature. The reaction volume
was usually 10 µL. After the reaction, Succinate-GloTM Hydroxylase assay was conducted in the
corresponding 96-well or 384-well plate. 50 µM DHB was set as a positive control in each plate.
4.7. Statistical Analysis
All the 3D culture assay images were acquired by Nikon microscope and were quantified with
the Nikon analysis software. Results are reported as mean ± S.E.M; the significance of difference
was assessed by independent Student’s t-test. p < 0.05 represents statistical significance and p < 0.01
represents sufficiently statistical significance. All reported p values were 2-tailed.
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